XML 57 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jul. 01, 2022
Jun. 30, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]                
One-time payment     $ (56.9)          
Revenues     2,936.2     $ 3,452.8 $ 8,758.5 $ 11,120.0
Sanofi Collaboration Agreement, Antibody                
Disaggregation of Revenue [Line Items]                
Percentage share of profits to reimburse collaborating party         10.00%      
Percentage of share of profits used to reimburse collaborating party for trial costs 20.00% 10.00%            
Revenue, remaining performance obligation, variable consideration amount     100.0       100.0  
Sanofi Collaboration Agreement, Antibody | Sales Milestone Three                
Disaggregation of Revenue [Line Items]                
Revenues       $ 50.0        
Levels of twelve-month sales at which sales milestone payments would be received       $ 2,000.0        
Period for achieving sales target for milestone payment, rolling basis       12 months        
Sanofi Collaboration Agreement, Antibody | Sales Milestone Four                
Disaggregation of Revenue [Line Items]                
Levels of twelve-month sales at which sales milestone payments would be received             $ 2,500.0  
Period for achieving sales target for milestone payment, rolling basis             12 months  
Revenue, remaining performance obligation, variable consideration amount     $ 50.0       $ 50.0  
Sanofi Collaboration Agreement, Antibody | Sales Milestone Two                
Disaggregation of Revenue [Line Items]                
Revenues           50.0    
Levels of twelve-month sales at which sales milestone payments would be received           $ 1,500.0    
Period for achieving sales target for milestone payment, rolling basis             12 months  
Sanofi Collaboration Agreement, Antibody | Minimum                
Disaggregation of Revenue [Line Items]                
Percentage of trial costs required to be funded by collaborating party             80.00%  
Percentage share of profits to reimburse collaborating party             30.00%  
Sanofi Collaboration Agreement, Antibody | Maximum                
Disaggregation of Revenue [Line Items]                
Percentage of trial costs required to be funded by collaborating party             100.00%  
Percentage share of profits to reimburse collaborating party             50.00%